Shandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets

Stock News03-04 16:34

Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178574727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 16:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178574727","market":"nz","top_or_hot":-1,"title":"Shandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets","media":"Stock News","content":"<p>Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Xinhua Pharmaceutical Granted Drug Registration Certificate for Entacapone Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-04 16:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1178574727","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178574727","pubTimestamp":1772613259,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","00719":"山东新华制药股份"},"translate_title":"山东新华制药获恩他卡朋片药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"Shandong Xinhua Pharmaceutical (00719) announced that it has recently received the Drug Registration Certificate for Entacapone Tablets from the National Medical Products Administration. The product serves as an adjunct therapy to standard medications such as levodopa/benserazide or levodopa/carbidopa, intended for the treatment of Parkinson's disease and end-of-dose symptoms that are not adequately controlled by these drugs. Entacapone Tablets are classified as a Category B drug in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance (2025). According to relevant statistics, sales of Entacapone Tablets in China's public medical institutions reached approximately RMB 286 million in 2024. The recent approval of Entacapone Tablets expands Shandong Xinhua's product portfolio and is expected to enhance the company's overall competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178574727","isCrawlerRequest":true}